Palexia Retard

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia Retard (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release oral tablet for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when a continuous opioid analgesic is required. GNH India supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sa Grünenthal N.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palexia Retard is an opioid analgesic that acts within the central nervous system to alleviate pain associated with several chronic conditions.

Chronic low back pain: provides sustained relief of moderate to severe pain over a 24‑hour period.
Osteoarthritis pain: reduces pain intensity and improves functional mobility.
Neuropathic pain associated with diabetic peripheral neuropathy: helps control persistent neuropathic discomfort.
Cancer‑related chronic pain: contributes to long‑term pain control as part of multimodal therapy.
Post‑surgical chronic pain syndromes: assists in managing lingering pain after major surgical procedures.

How It Works

Tapentadol Hydrochloride exerts analgesic activity through a dual mechanism: it is a μ‑opioid receptor agonist that inhibits nociceptive transmission and a norepinephrine reuptake inhibitor that enhances descending inhibitory pain pathways. This combined action reduces the perception of pain while modulating spinal cord neurotransmission, providing effective relief for moderate to severe chronic pain.

Side Effects

Tapentadol Hydrochloride may cause a range of adverse reactions, from mild to serious, that should be monitored during therapy.

Common Side Effects

Nausea
Constipation
Dizziness
Somnolence
Headache
Dry mouth

Serious or Rare Side Effects

Respiratory depression
Seizures
Severe hypotension
Serotonin syndrome
Allergic reactions (rash, angioedema)
Dependence or abuse potential

Precautions & Warnings

When prescribing Tapentadol Hydrochloride, clinicians should consider several safety aspects to minimize risk.

Assess pain severity and opioid tolerance: ensure the patient requires a strong opioid.
Review medical history: avoid use in patients with significant respiratory disease.
Monitor for signs of misuse or dependence: educate patients on proper use.
Caution in renal or hepatic impairment: dose adjustments may be needed.
Avoid abrupt discontinuation: taper gradually to prevent withdrawal.
Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Avoid Interactions

Tapentadol Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Concomitant use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may increase respiratory depression risk.
MAO‑inhibitors: may precipitate hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely)

Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may raise serotonin syndrome risk.
CYP2D6 inhibitors (e.g., quinidine): can increase tapentadol plasma levels.
Antihistamines or anticholinergics: may enhance sedation and anticholinergic effects.
Diuretics: may potentiate hypotensive effects.
Alcohol: additive central nervous system depression.

Frequently Asked Questions

Palexia Retard is a prolonged‑release formulation of tapentadol hydrochloride indicated for the management of moderate to severe chronic pain, such as that arising from low back pain, osteoarthritis, neuropathic conditions, cancer‑related pain, or persistent post‑surgical pain in adult patients.

Tapentadol combines μ‑opioid receptor agonism with inhibition of norepinephrine reuptake. The opioid activity blocks pain signals at the spinal level, while increased norepinephrine enhances descending inhibitory pathways, together reducing the perception of pain.

The dose of Palexia Retard is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, renal and hepatic function, and overall clinical condition. The prescriber determines the appropriate strength and dosing schedule.

Tapentadol is classified as a pregnancy‑category C medication; it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding is generally not recommended while receiving this opioid.

To place an order, submit an enquiry on the Palexia Retard product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with traditional opioids such as morphine, tapentadol offers a dual mechanism that may provide effective analgesia with a potentially lower incidence of some opioid‑related side effects, such as constipation, due to its norepinephrine reuptake inhibition component.

Store Palexia Retard tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and heat. Keep the container tightly closed and out of reach of children.

Palexia Retard is taken orally as a whole tablet, usually once daily, with or without food. Tablets should not be split, crushed, or chewed, as this can alter the extended‑release profile.

Serious risks include respiratory depression, severe hypotension, seizures, serotonin syndrome (especially with serotonergic drugs), and the potential for dependence, abuse, or withdrawal upon discontinuation.

Palexia Retard is contraindicated in patients with known hypersensitivity to tapentadol or any excipients, those with significant respiratory depression, acute or severe asthma, or gastrointestinal obstruction, and it should be avoided in individuals taking MAO‑inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.